company background image
ALIKO logo

Ikonisys ENXTPA:ALIKO Stock Report

Last Price

€1.40

Market Cap

€16.7m

7D

-4.8%

1Y

6.9%

Updated

20 Nov, 2024

Data

Company Financials +

ALIKO Stock Overview

A cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. More details

ALIKO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Ikonisys S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ikonisys
Historical stock prices
Current Share Price€1.40
52 Week High€1.80
52 Week Low€1.25
Beta0.70
11 Month Change-10.83%
3 Month Change-4.76%
1 Year Change6.87%
33 Year Change-48.72%
5 Year Changen/a
Change since IPO-64.29%

Recent News & Updates

Recent updates

Shareholder Returns

ALIKOFR Medical EquipmentFR Market
7D-4.8%2.7%-0.3%
1Y6.9%26.7%-3.5%

Return vs Industry: ALIKO underperformed the French Medical Equipment industry which returned 28.4% over the past year.

Return vs Market: ALIKO exceeded the French Market which returned -2.5% over the past year.

Price Volatility

Is ALIKO's price volatile compared to industry and market?
ALIKO volatility
ALIKO Average Weekly Movement3.7%
Medical Equipment Industry Average Movement5.4%
Market Average Movement4.5%
10% most volatile stocks in FR Market9.2%
10% least volatile stocks in FR Market2.2%

Stable Share Price: ALIKO has not had significant price volatility in the past 3 months compared to the French market.

Volatility Over Time: ALIKO's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
202110Mario Crovettoikonisys.com

Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. It offers Ikoniscope Robotic Microscopes, including Ikoniscope20 that provides automated slide handling, slide scanning, and real-time image capture and analysis; and Ikoniscope20max that automates the fluorescence microscopy solution. The company also provides oncoFISH bladder that allows scanning and analysis of cells from a voided urine sample; oncoFISH her2, a microscopy application for the determination of the HER2 status of tissue sections from breast tissue biopsies; oncoFISH anaplastic lymphoma kinase (ALK), a microscopy application for the FISH based detection of gene rearrangements commonly associated with non-small cell lung carcinoma; oncoFISH PTEN, a microscopy application for the FISH based detection of deletions of the PTEN gene, which is prostate tissue biopsies; circulating tumor cells for characterization of individual tumor cells and ctDNA for global tumor genotype information; Ikonisoft explorer, a FISH scanning application for analysis of cell suspension deposited on a slide that has been hybridized with desired combination of FISH probes; and IkoniWAN Gateway, a validated remote access solution for Ikoniscope digital microscopy systems.

Ikonisys S.A. Fundamentals Summary

How do Ikonisys's earnings and revenue compare to its market cap?
ALIKO fundamental statistics
Market cap€16.67m
Earnings (TTM)-€2.70m
Revenue (TTM)€471.50k

33.4x

P/S Ratio

-5.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALIKO income statement (TTM)
Revenue€471.50k
Cost of Revenue€280.18k
Gross Profit€191.32k
Other Expenses€2.89m
Earnings-€2.70m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.24
Gross Margin40.58%
Net Profit Margin-572.54%
Debt/Equity Ratio26.9%

How did ALIKO perform over the long term?

See historical performance and comparison